Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
In non-small cell lung cancer (NSCLC), the most prevalent driver mutations in epidermal growth factor receptor (_EGFR_) are deletions in exon 19 (Ex19del) and L858R mutations in exon 21, which comprise approximately 90% of all _EGFR_ mutations. In contrast, exon 20 insertion (Ex20ins) mutations are...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.21.154 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525491082723328 |
|---|---|
| author | Sebastian Kraus |
| author_facet | Sebastian Kraus |
| author_sort | Sebastian Kraus |
| collection | DOAJ |
| description | In non-small cell lung cancer (NSCLC), the most prevalent driver mutations in epidermal growth factor receptor (_EGFR_) are deletions in exon 19 (Ex19del) and L858R mutations in exon 21, which comprise approximately 90% of all _EGFR_ mutations. In contrast, exon 20 insertion (Ex20ins) mutations are relatively rare, accounting for up to 12% of _EGFR_ mutations and ranking third in frequency. Given the many treatment options available for NSCLC and the increasing understanding of the interactions between mutations and common therapies in the palliative stages, comprehensive next-generation sequencing (NGS) is recommended at the initial stage, particularly for adenocarcinomas. _EGFR_ Ex20ins mutations are a molecularly heterogeneous group of over 100 variants that are identified through NGS using tumor DNA. The high prevalence of these _EGFR_ mutations in NSCLC has led to significant research efforts aimed at optimizing therapeutic options for patients. This review article highlights the key findings from recent studies in the field of _EGFR_ mutations in NSCLC.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Wolf-Dieter Janthur, Cantonal Hospital Aarau, Aarau, Switzerland
Dr David König, University Hospital Basel, Basel, Switzerland
One anonymous peer reviewer
Received on May 13, 2024; accepted after peer review on September 15, 2024; published online on October 02, 2024. |
| format | Article |
| id | doaj-art-cef8385fa5c2443e8dad9871d7afdb7c |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-cef8385fa5c2443e8dad9871d7afdb7c2025-01-17T12:15:34ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062024-10-01213Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLCSebastian KrausIn non-small cell lung cancer (NSCLC), the most prevalent driver mutations in epidermal growth factor receptor (_EGFR_) are deletions in exon 19 (Ex19del) and L858R mutations in exon 21, which comprise approximately 90% of all _EGFR_ mutations. In contrast, exon 20 insertion (Ex20ins) mutations are relatively rare, accounting for up to 12% of _EGFR_ mutations and ranking third in frequency. Given the many treatment options available for NSCLC and the increasing understanding of the interactions between mutations and common therapies in the palliative stages, comprehensive next-generation sequencing (NGS) is recommended at the initial stage, particularly for adenocarcinomas. _EGFR_ Ex20ins mutations are a molecularly heterogeneous group of over 100 variants that are identified through NGS using tumor DNA. The high prevalence of these _EGFR_ mutations in NSCLC has led to significant research efforts aimed at optimizing therapeutic options for patients. This review article highlights the key findings from recent studies in the field of _EGFR_ mutations in NSCLC. PEER REVIEWED ARTICLE **Peer reviewers:** Dr Wolf-Dieter Janthur, Cantonal Hospital Aarau, Aarau, Switzerland Dr David König, University Hospital Basel, Basel, Switzerland One anonymous peer reviewer Received on May 13, 2024; accepted after peer review on September 15, 2024; published online on October 02, 2024.https://doi.org/10.36000/HBT.OH.2024.21.154 |
| spellingShingle | Sebastian Kraus Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC healthbook TIMES. Oncology Hematology |
| title | Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC |
| title_full | Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC |
| title_fullStr | Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC |
| title_full_unstemmed | Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC |
| title_short | Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC |
| title_sort | navigating the evolving treatment paradigm for egfr mutant nsclc |
| url | https://doi.org/10.36000/HBT.OH.2024.21.154 |
| work_keys_str_mv | AT sebastiankraus navigatingtheevolvingtreatmentparadigmforegfrmutantnsclc |